Please login to the form below

Not currently logged in
Email:
Password:

S-A takeover approach rejected

Sanofi-aventis' suspected takeover approach for Genzyme has been rejected, according to two sources

Sanofi-aventis' (S-A) suspected takeover approach for Genzyme has been rejected, according to two sources.

Analysts have speculated that Genzyme, one of the world's leading biotechnology companies, could command at least $22bn, or $80 a share – a 48 per cent profit over Genzyme's closing price the day before S-A made its approach. It is thought that investors will insist on at least $20bn in a sale.

Genzyme could accrue an annual revenue of $6.6bn by 2013 if it resolves manufacturing defects that resulted in the figure dropping to $4.5bn in 2009.

GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) have also been rumoured to be bidding for Genzyme.

S-A and Genzyme have refused to comment on the claims.

27th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Asit Parikh
Gut instincts lead Takeda to GI pipeline success
Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy...
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home...
The importance of health literacy in patient recruitment materials
Have you ever read something that instantly made you want to read on? Or have you begun to read something, and eventually given up because it didn’t resonate with you?...

Infographics